Bank of New York Mellon’s BioLineRX BLRX Stock Holding History

Bank of New York Mellon’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-30	Closed	-$20K	–	4357
2017 Q3	$20K	Sell	30 -5	-14%	-$3.11K	﹤0.01%	4213
2017 Q2	$18K	Sell	35 -5	-13%	-$2.57K	﹤0.01%	4239
2017 Q1	$23K	Buy	40 +10	+33%	+$6.44K	﹤0.01%	4221
2016 Q4	$16K	Sell	30 -1	-3%	-$621	﹤0.01%	4228
2016 Q3	$21K	Buy	31 +1	+3%	+$533	﹤0.01%	4213
2016 Q2	$14K	Hold	30	–	–	﹤0.01%	4284
2016 Q1	$18K	Hold	30	–	–	﹤0.01%	4173
2015 Q4	$23K	Sell	30 -3	-9%	-$2.49K	﹤0.01%	4265
2015 Q3	$30K	Buy	33 +3	+10%	+$3.2K	﹤0.01%	4295
2015 Q2	$47K	Hold	30	–	–	﹤0.01%	4169
2015 Q1	$38K	Hold	30	–	–	﹤0.01%	4158
2014 Q4	$29K	Hold	30	–	–	﹤0.01%	4187
2014 Q3	$27K	Hold	30	–	–	﹤0.01%	4186
2014 Q2	$37K	Hold	30	–	–	﹤0.01%	4099
2014 Q1	$40K	Hold	30	–	–	﹤0.01%	4104
2013 Q4	$50K	Hold	30	–	–	﹤0.01%	4112
2013 Q3	$39K	Hold	30	–	–	﹤0.01%	4068
2013 Q2	$29K	Buy	+30	New	+$31.1K	﹤0.01%	4084

Other funds holding BLRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon's BLRX Position: Q4 2017 in Review

Bank of New York Mellon sold out of BioLineRX (BLRX) in Q4 2017, closing a stake of 30 shares — an estimated $20K sold.

Bank of New York Mellon first reported a position in BLRX in Q2 2013 and held it in 18 quarters. The position peaked at $50K in Q4 2013. 28 funds tracked by Wall St. Rank hold BLRX as of Q4 2017.

Bank of New York Mellon reported no remaining BioLineRX position as of Q4 2017 after selling out during the quarter.
Bank of New York Mellon sold 30 BioLineRX shares in Q4 2017, an estimated $20K.
Bank of New York Mellon first reported a position in BioLineRX in Q2 2013 and held it in 18 quarters.
Bank of New York Mellon's BioLineRX position peaked at $50K in Q4 2013.
28 funds tracked by Wall St. Rank held BioLineRX as of Q4 2017.

Based on Bank of New York Mellon's 13F filing for Q4 2017, filed 9 Feb 2018.